Neostem Inc (NASDAQ:NBS)

CAPS Rating: 2 out of 5

Recs

0
Player Avatar andrejax11 (36.46) Submitted: 1/13/2013 8:22:22 PM : Outperform Start Price: $6.20 NBS Score: -10.99

This stock is poised to go higher given NBS' strategic position within the stem cell industry, their cash flow from cell storage off setting cash burn, the number and stage of clinical trials as well as longer term trending in the cell industry as a whole.

Featured Broker Partners


Advertisement